Not affiliated with Eli Lilly or any pharmaceutical manufacturer. Retatrutide has not been approved by the FDA for any use. This website is for educational purposes only.

Retatrutide Journal

News, Research, and Obesity Insights

A plain-language reference on retatrutide (LY3437943): trial data, mechanism, and how it compares to semaglutide and tirzepatide.

Retatrutide 2026: what it is and everything confirmed so far

Study Results

Retatrutide 2026: Everything Confirmed So Far

October 2026: what retatrutide is, how it works, what its five Phase 3 trials found, and where it stands with the FDA.

Skin Sensitivity (Dysesthesia) from Retatrutide: The Side Effect Nobody Talks About

Skin sensitivity, tingling or burning was reported by 4.4% to 20.9% of trial participants on 12 mg. What is known about why it happens and whether it goes away.

RetaWeightLoss.com

October 3, 2026

Approval Status

Retatrutide FDA Approval Status: October 2026 Update

October 2026: TRIUMPH-1 and TRIUMPH-2 published in full, BLA planned for Q1 2027. Full trial status, FDA review timeline, and what could move the date.

RetaWeightLoss.com

October 3, 2026

Study Results

Retatrutide Side Effects: Complete Guide to the Trial Data

Retatrutide's trial side effects were mostly gastrointestinal (nausea 42.4% on the top dose in TRIUMPH-1), with one that stands out: dysesthesia, at 12.5%. What the data show about how long they lasted.

RetaWeightLoss.com

October 3, 2026